[HTML][HTML] The integrated genomic landscape of thymic epithelial tumors

M Radovich, CR Pickering, I Felau, G Ha, H Zhang… - Cancer cell, 2018 - cell.com
Thymic epithelial tumors (TETs) are one of the rarest adult malignancies. Among TETs,
thymoma is the most predominant, characterized by a unique association with autoimmune …

[HTML][HTML] Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures

X Zhang, P Zhang, A Cong, Y Feng, H Chi… - Frontiers in …, 2023 - frontiersin.org
Thymic epithelial tumors (TETs) are a rare and diverse group of neoplasms characterized by
distinct molecular signatures. This review delves into the complex molecular networks of …

[HTML][HTML] An overview on molecular characterization of thymic tumors: old and new targets for clinical advances

V Tateo, L Manuzzi, C Parisi, A De Giglio, D Campana… - Pharmaceuticals, 2021 - mdpi.com
Thymic tumors are a group of rare mediastinal malignancies that include three different
histological subtypes with completely different clinical behavior: the thymic carcinomas, the …

[HTML][HTML] Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

Y Katsuya, H Horinouchi, T Seto, S Umemura… - European Journal of …, 2019 - Elsevier
Introduction Thymic carcinoma (TC) is a rare cancer with a poor prognosis and limited
treatment options, especially after relapse. Methods In this open-label, two-stage …

A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma

HS Lee, HJ Jang, M Ramineni, DY Wang… - Clinical Cancer …, 2023 - AACR
Purpose: We report the results of a phase II, randomized, window-of-opportunity trial of
neoadjuvant durvalumab versus durvalumab plus tremelimumab followed by surgery in …

[HTML][HTML] The immune landscape of human thymic epithelial tumors

Z Xin, M Lin, Z Hao, D Chen, Y Chen, X Chen… - Nature …, 2022 - nature.com
Human thymic epithelial tumors (TET) are common malignancies in the anterior
mediastinum with limited biological understanding. Here we show, by single cell analysis of …

Predicting master transcription factors from pan-cancer expression data

J Reddy, MAS Fonseca, RI Corona, R Nameki… - Science …, 2021 - science.org
Critical developmental “master transcription factors”(MTFs) can be subverted during
tumorigenesis to control oncogenic transcriptional programs. Current approaches to …

[HTML][HTML] Analysis of the tumor microenvironment and mutation burden identifies prognostic features in thymic epithelial tumors

X Hou, S Lin, Y Liu, K Wang, Z Yu, J Jia… - American Journal of …, 2022 - ncbi.nlm.nih.gov
Thymic epithelial tumors (TETs) are one of the rarest adult malignancies in the anterior
mediastinum. Thymic carcinomas (TCs) are less prevalent among TETs, but they are more …

[HTML][HTML] A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma

OB Gbolahan, RF Porter, JT Salter… - Journal of Thoracic …, 2018 - Elsevier
Introduction Thymoma and thymic carcinoma (TC) are neoplastic diseases with reported
chemosensitivity to a broad range of agents. However, because of the rarity of these …

[HTML][HTML] Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors

K Palamaris, LM Tzimou, G Levidou… - International Journal of …, 2023 - mdpi.com
Histone deacetylases (HDACs) are core epigenetic factors, with pivotal roles in the
regulation of various cellular procedures, and their deregulation is a major trait in the …